{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:02:32Z","timestamp":1789923752875,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T00:00:00Z","timestamp":1432166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00125-015-3608-6","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T11:13:36Z","timestamp":1432120416000},"page":"1745-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Incretin-based therapies: where will we be 50\u00a0years from now?"],"prefix":"10.1007","volume":"58","author":[{"given":"Juris J.","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"3608_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46\u201354","journal-title":"Diabetologia"},{"key":"3608_CR2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/diabetes.50.7.1588","volume":"50","author":"CF Deacon","year":"2001","unstructured":"Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50:1588\u20131597","journal-title":"Diabetes"},{"key":"3608_CR3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, \u00d8rskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741\u2013744","journal-title":"Diabetologia"},{"key":"3608_CR4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728\u2013742","journal-title":"Nat Rev Endocrinol"},{"key":"3608_CR5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diab Endocrinol 2:885\u2013893","journal-title":"Lancet Diab Endocrinol"},{"key":"3608_CR6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","volume":"124","author":"MA Nauck","year":"2011","unstructured":"Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124:S3\u2013S18","journal-title":"Am J Med"},{"key":"3608_CR7","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s00125-013-2953-6","volume":"56","author":"MA Nauck","year":"2013","unstructured":"Nauck MA, Baranov O, Ritzel RA, Meier JJ (2013) Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 56:1878\u20131883","journal-title":"Diabetologia"},{"key":"3608_CR8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","volume":"378","author":"AA Tahrani","year":"2011","unstructured":"Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182\u2013197","journal-title":"Lancet"},{"key":"3608_CR9","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.2337\/db14-0935","volume":"63","author":"S Madsbad","year":"2014","unstructured":"Madsbad S, Holst JJ (2014) GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 63:3172\u20133174","journal-title":"Diabetes"},{"key":"3608_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.beem.2004.08.007","volume":"18","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Nauck MA (2004) Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide\/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab 18:587\u2013606","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3608_CR11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1055\/s-2004-826176","volume":"36","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Nauck MA (2004) GIP as a potential therapeutic agent? Horm Metab Res 36:859\u2013866","journal-title":"Horm Metab Res"},{"key":"3608_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27\u201336","journal-title":"Nat Med"},{"key":"3608_CR13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-4-431-75452-7_17","volume-title":"Pancreatic beta cell in health and disease","author":"MA Nauck","year":"2008","unstructured":"Nauck MA, Meier JJ (2008) Incretins and regulation of insulin secretion. In: Seino S, Bell GI (eds) Pancreatic beta cell in health and disease. Springer, Tokyo, pp 335\u2013378"},{"key":"3608_CR14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70218-3","volume":"2","author":"S Madsbad","year":"2014","unstructured":"Madsbad S, Dirksen C, Holst JJ (2014) Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diab Endocrinol 2:152\u2013164","journal-title":"Lancet Diab Endocrinol"},{"key":"3608_CR15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","volume":"366","author":"G Mingrone","year":"2012","unstructured":"Mingrone G, Panunzi S, De Gaetano A et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577\u20131585","journal-title":"N Engl J Med"},{"key":"3608_CR16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","volume":"21","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Yusta B et al (2015) GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 21:379\u2013391","journal-title":"Cell Metab"},{"key":"3608_CR17","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606\u20131616","journal-title":"Lancet"},{"key":"3608_CR18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2337\/dc07-1441","volume":"31","author":"KM Utzschneider","year":"2008","unstructured":"Utzschneider KM, Tong J, Montgomery B et al (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31:108\u2013113","journal-title":"Diabetes Care"},{"key":"3608_CR19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 37:1443\u20131451","journal-title":"Int J Obes (Lond)"},{"key":"3608_CR20","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","volume":"34","author":"U Kielgast","year":"2011","unstructured":"Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:1463\u20131468","journal-title":"Diabetes Care"},{"key":"3608_CR21","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","volume":"114","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Drucker DJ (2014) Cardiovascular actions of incretin-based therapies. Circ Res 114:1788\u20131803","journal-title":"Circ Res"},{"key":"3608_CR22","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2013) Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest 123:2730\u20132736","journal-title":"J Clin Invest"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-015-3608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-015-3608-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-015-3608-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:53:55Z","timestamp":1558612435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-015-3608-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["3608"],"URL":"https:\/\/doi.org\/10.1007\/s00125-015-3608-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}